HAL (France)open access
First-line biologic therapy selection highly impacts ulcerative colitis outcomes: results from the APPETISER study
Inflammatory bowel diseases, Amp, Ulcerative colitis, 2, Therapeutic sequencing, Biological products, 1, Ve patients
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 398713
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.